Crestwood Advisors Group LLC Grows Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Crestwood Advisors Group LLC grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 12.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,840 shares of the medical research company’s stock after purchasing an additional 527 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Exact Sciences were worth $272,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Thompson Investment Management Inc. increased its position in shares of Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after purchasing an additional 36,505 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after purchasing an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. increased its position in shares of Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after purchasing an additional 11,800 shares during the last quarter. Zacks Investment Management purchased a new stake in shares of Exact Sciences during the 3rd quarter valued at about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after purchasing an additional 125,192 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Down 3.3 %

NASDAQ EXAS opened at $48.50 on Thursday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The company has a market capitalization of $9.01 billion, a P/E ratio of -8.71 and a beta of 1.24. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The stock has a 50 day moving average price of $54.34 and a 200-day moving average price of $59.87.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. As a group, equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Citigroup reduced their target price on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Scotiabank increased their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday. Stifel Nicolaus reduced their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group reduced their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Bank of America reduced their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $71.94.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.